Angiotensin II Receptor Blocker Offered as Standalone or Combination Hypertension Therapy

 

April 21, 2011

Edarbi is a once-daily oral therapy for use alone or in combination with other antihypertensive medications to treat hypertension. Edarbi (azilsartan medoxomil), by Takeda Pharmaceutical, is available by prescription for adults in U.S. pharmacies. Edarbi is a once-daily oral therapy for use alone and for use in combination with other antihypertensive medications.

Pivotal phase 3 studies showed it (80 mg/day) was statistically superior to the highest approved doses of two commonly prescribed ARBs, olmesartan medoxomil (40 mg/day) and valsartan (320 mg/day) in lowering both clinic systolic blood pressure (SBP) and 24-hour mean SBP as measured by Ambulatory Blood Pressure Monitoring (ABPM).

The U.S. Food and Drug Administration (FDA) cleared the high blood pressure medication in April 2011.

For more information: www.takeda.com

The content of this field is kept private and will not be shown publicly.
By submitting this form, you accept the Mollom privacy policy.